Frazier Life Sciences
Overview
Frazier Life Sciences is a venture capital firm specializing in investments in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London. Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm has raised over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London. Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm has raised over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.
Investment Focus
- Innovative biopharmaceutical companies addressing significant medical needs
- Strong management teams
- Potential for substantial growth and value creation
Portfolio Companies
Get the full list of 54,000+ investors
Frazier Life Sciences and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Frazier Life Sciences
What sectors does Frazier Life Sciences invest in?
Frazier Life Sciences invests in Healthcare, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Washington, United States. Frazier Life Sciences is listed as a venture capital in the ConnectSafely investor database.
What stage does Frazier Life Sciences invest at?
Frazier Life Sciences backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 5M - 50M.
Which regions does Frazier Life Sciences invest in?
Frazier Life Sciences invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
What companies has Frazier Life Sciences invested in?
Frazier Life Sciences's portfolio includes Mirum Pharmaceuticals, Syndax Pharmaceuticals, Phathom Pharmaceuticals, BridgeBio Pharma, Amunix Pharmaceuticals, Alpine Immune Sciences, Arcutis Biotherapeutics and NewAmsterdam Pharma.
Last updated · Source: ConnectSafely investor database
